Seattle start-up Olympic Ophthalmics has received US Food and Drug Administration (FDA) approval for its iTEAR100 device, a prescription neurostimulation therapy to increase tear production in adult
Glasgow-based optometry tech firm IbisVision is looking to raise £5m (NZ$9.4m) in the US to fund the roll out its remote-optometry technology internationally. Designed to support remote monitoring and
Device Technologies NZ is introducing a new Oertli phacoemulsification system designed to save consumables costs and the environment.
Launched during RANZCO’s virtual congress, Quantel Medical’s C.Stim offers new intense pulsed light (IPL) technology for the treatment of the root causes of dry eye: meibomian gland dysfunction, inflammation and Demodex.
The RANZCO New Zealand branch annual scientific meeting from 22 April 2022 features local and international speakers, including keynotes Professor Helen Danesh-Meyer, Associate Professor Samantha Fraser-Bell, Nicola Dunlop, Dr Rachael Niederer and Associate Professor Bruce Hadden.
On behalf of the organising committee, I am pleased to invite and welcome you to the 2022 RANZCO New Zealand Branch Annual Scientific Meeting and the New Zealand Ophthalmic Nurses Group Meeting, on Friday 22 and Saturday 23 April, with the registrar programme held on Thursday 21 April.
RANZCO NZ 2022: the details The RANZCO New Zealand Branch Annual Scientific Meeting is a hybrid (in-person and virtual) conference running from Friday 22 to Saturday 23 April 2022 in BlenheimA
The US Food and Drug Administration (FDA) has approved the first generic of Allergan’s Restasis (cyclosporine ophthalmic emulsion) 0.05% single-use eye drops to increase tear production in dry eye patients.
Alcon has once again expanded its range of preservative-free eye drops with the addition of Systane COMPLETE PRESERVATIVE-FREE Lubricant Eye Drops. This lubricating eye drop combines the long-lasting formulation of Systane COMPLETE with a multi-dose, preservative-free bottle.
RNFL thickness: Alzheimer’s biomarker?
As the stresses of the global pandemic continue to take their toll on the medical profession, a new report has found that ophthalmologists appear to be coping better than their non-ophthalmological colleagues but are still struggling under the pressure.
Luxturna is now funded for patients in Australia with confirmed biallelic RPE65 mutation-associated retinal dystrophy that leads to vision loss and, frequently, complete blindness. The move follows a